Skip to main content

Neurotoxicity De-Risking in Preclinical Drug Discovery

Objective

The adverse effects of pharmaceuticals on the central or peripheral nervous systems are poorly predicted by the current in vitro and in vivo preclinical studies performed during Research and Development (R&D) process. Therefore, increasing the predictivity of the preclinical toolbox is a clear need, and would benefit to human volunteers/patients (safer drugs) and Pharmaceutical Industry (reduced attrition). By combining top level scientists in neurobiology/toxicology with successful software developers, the NeuroDeRisk | Neurotoxicity De-Risking in Preclinical Drug Discovery Consortium will aim at tackling three of the most challenging adverse effects: seizures, psychological/psychiatric changes, and peripheral neuropathies. Our approach will be global, starting with an in-depth evaluation of knowledge on mechanisms of neurotoxicity (biological pathways as well as chemical structures and descriptors, using in particular historical data). Then we will search for innovative tools, assays and studies covering in silico, in vitro and in vivo approaches. This will include in particular: molecular design platform, artificial intelligence, human induced pluripotent stem cells, blood-brain-barrier models, immunohistochemistry, transcriptomics, RNA editing biomarkers, video-monitoring and telemetry of animals, pharmacokinetics, etc. The last step will aim at combining these tools in an integrated platform for better risk-assessment and decision-points throughout R&D process, and thus better protection of human volunteers and patients.

Field of science

  • /medical and health sciences/medical biotechnology/cells technologies/stem cells
  • /natural sciences/computer and information sciences/artificial intelligence
  • /natural sciences/biological sciences/neurobiology

Call for proposal

H2020-JTI-IMI2-2017-13-two-stage
See other projects for this call

Funding Scheme

IMI2-RIA - Research and Innovation action

Coordinator

UNIVERSITAT WIEN
Address
Universitatsring 1
1010 Wien
Austria
Activity type
Higher or Secondary Education Establishments
EU contribution
€ 594 450

Participants (17)

MEDIZINISCHE UNIVERSITAET WIEN
Austria
EU contribution
€ 372 200
Address
Spitalgasse 23
1090 Wien
Activity type
Higher or Secondary Education Establishments
FARMACEUTSKI FAKULTET UNIVERZITETAU BEOGRADU
Serbia
EU contribution
€ 696 150
Address
Vojvode Stepe 450
52600 Belgrade
Activity type
Higher or Secondary Education Establishments
INTE:LIGAND SOFTWARE-ENTWICKLUNGS-UND CONSULTING GMBH
Austria
EU contribution
€ 341 400
Address
Clemens Maria Hofbauer Gasse 6
2344 Maria Enzersdorf
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
ITA-SUOMEN YLIOPISTO
Finland
EU contribution
€ 804 900
Address
Yliopistonranta 1 E
70211 Kuopio
Activity type
Higher or Secondary Education Establishments
UNIVERSITA DEGLI STUDI DI FIRENZE
Italy
EU contribution
€ 391 500
Address
Piazza San Marco 4
50121 Florence
Activity type
Higher or Secondary Education Establishments
ICETA INSTITUTO DE CIENCIAS, TECNOLOGIAS E AGROAMBIENTE DA UNIVERSIDADE DO PORTO
Portugal
EU contribution
€ 403 500
Address
Rua D Manuel Ii Apartado 55142
4051 401 Porto
Activity type
Research Organisations
UPPSALA UNIVERSITET
Sweden
EU contribution
€ 307 400
Address
Von Kraemers Alle 4
751 05 Uppsala
Activity type
Higher or Secondary Education Establishments
ALCEDIAG
France
EU contribution
€ 583 300
Address
Route Des Michels La Corneirelle
13790 Peynier
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
UNIVERSITE CLERMONT AUVERGNE
France
EU contribution
€ 429 400
Address
49 Boulevard Francois Mitterrand
63000 Clermont-ferrand
Activity type
Higher or Secondary Education Establishments
A. PERSIDIS & SIA OE
Greece
EU contribution
€ 406 800
Address
Rodopoleos Street 34
167 77 Athina
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
SANOFI-AVENTIS RECHERCHE & DEVELOPPEMENT
France
EU contribution
€ 0
Address
Pierre Brossolette 1
91380 Chilly Mazarin
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
ASTRAZENECA AB
Sweden
EU contribution
€ 0
Address
Vastra Maelarhamnen
151 85 Sodertaelje
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
FUJIFILM CELLULAR DYNAMICS INC
United States
EU contribution
€ 0
Address
Science Drive 525 Suite 200
53711 Madison Wi
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
MERCK SHARP & DOHME CORP
United States
EU contribution
€ 0
Address
One Merck Drive
08889 Whitehouse Station Nj
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
NOVARTIS PHARMA AG
Switzerland
EU contribution
€ 0
Address
Lichtstrasse 35
4056 Basel
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
PFIZER LIMITED
United Kingdom
EU contribution
€ 0
Address
Ramsgate Road
CT13 9NJ Sandwich
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
UCB BIOPHARMA SRL
Belgium
EU contribution
€ 0
Address
Allee De La Recherche 60
1070 Bruxelles
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)